MN663 Unit 6 seminar reflection example

Reviewed by Elspeth Marlowe, MSN, RN PMHNP Diagnosis and Management Across the Lifespan I Purdue University Global Free custom sample in 24 to 48h

This page holds a complete MN663 Unit 6 seminar reflection example in true form. The author arrived convinced that brexpiprazole, approved in 2023 for agitation in Alzheimer's dementia, settled the case of a composite 84-year-old in memory care who strikes out during evening care; a classmate's question about pain moved the group to a sequence that treats pain and routine first. Many sections pair this seminar with a reflection.

What this page holds

A new approval did not end the argument: the seminar behind MN663's Unit 6 reflection weighs brexpiprazole for a composite woman's evening agitation against pain, routine and a dated mortality warning. Searches like "mn 663 unit 6 assignment example", "mn663 unit 6 sample" and "mn663 unit 6 example" land here.

1

An Approved Drug Is Not an Answered Question: A Seminar Reflection on Agitation in Dementia

[Student Name]

Purdue University Global

MN663: PMHNP Diagnosis and Management Across the Lifespan I

Unit 6 Seminar Reflection

[Instructor Name]

[Date]

The case discussed is a composite prepared for teaching. Classmates are identified by role only.

What this part is doingThe title states the lesson in one line. A reader knows from it that the reflection concerns the difference between an approval and a decision for one patient.
2

Where I Started

The case was a composite 84-year-old woman with Alzheimer's dementia in a memory care unit who hits and scratches aides during evening care, most nights of the week. Two aides had been scratched, one badly enough to need first aid. I arrived at seminar with my answer ready: the FDA approved brexpiprazole in 2023 for agitation associated with dementia due to Alzheimer's disease, so the prescribing question had been answered for us, and every week of delay left aides at risk. I said so in the first ten minutes.

The Turn

A classmate who works in long-term care asked: "When was she last assessed for pain?" The case file answered in two places I had skimmed. She has knee osteoarthritis that was noted on admission and never treated, and her evening care begins with a shower, which her daughter says she has resisted her whole life. The agitation had a pattern, the same time, the same task and a painful knee being moved, and I had treated it as a symptom of dementia to be medicated rather than a behavior with causes to be found.

The group then read the label and the trial report together. Approval rested on two twelve-week trials that measured agitation with the Cohen-Mansfield Agitation Inventory, and the drug separated from placebo by a modest margin (Lee et al., 2023). The prescribing information carries the boxed warning, applied to atypical antipsychotics since 2005 (Otsuka America Pharmaceutical, 2023), that older adults with dementia-related psychosis treated with these drugs have an increased risk of death. Reading those two facts side by side changed my sense of what the approval meant. It meant the drug can help some patients modestly; it did not mean it should be the first step for this one.

What this part is doingThe turning point is placed where it happened and quoted as the classmate asked it. The reflection records what the author had skimmed, which is more honest than presenting the insight as the author's own.
3

The Sequence We Reached

The group borrowed the DICE approach, describe, investigate, create and evaluate, from an expert panel on neuropsychiatric symptoms of dementia (Kales et al., 2014). Described, the behavior occurs during evening showers. Investigated, likely causes include untreated knee pain, a lifelong dislike of showers and evening fatigue. Created, the plan treats the knee pain with scheduled acetaminophen and reassesses, moves bathing to mid-morning when she is most settled and uses a sponge bath on difficult days, and assigns her most familiar aide to evening care. Evaluated, aides track episodes on a simple log for four weeks. Medication, including brexpiprazole, would be reconsidered only if agitation remains severe and places her or staff in danger despite these changes.

Why I Was So Sure

Looking back, I can see why the approval felt decisive. I had learned to look for evidence, and an FDA approval is a kind of evidence. I had also been moved by the aides' injuries, which felt urgent and concrete, while the risks of the drug felt abstract and statistical. And I had framed the question as which drug, not whether a drug. The classmate's question worked because it changed the frame: it asked what was causing the behavior before asking what would suppress it. I also realized that I had never met this woman, even on paper; I knew her diagnosis and her behavior, but not that she had hated showers for eighty years. The daughter's comment about showers was in the file the whole time, and it would have changed my reading on its own had I read the file as a history of a person rather than a list of problems.

The Disagreement

One disagreement was not resolved. A classmate who manages a memory care unit argued that four weeks is too long if an aide is seriously hurt in the meantime, and that the unit has a duty to its staff as well as to the patient. Others argued that most of the likely causes could be addressed within days and that the log would show quickly whether the changes were working. We agreed that an injury or escalation should prompt earlier review, but not on how early, and I think that question deserves an answer written into the unit's policy.

What I Will Do Differently

Before I propose any antipsychotic for an older adult, I will ask one question first: what has been done to find and treat the cause of this behavior, starting with pain? I will write the answer into the note so that the next clinician sees it, and if the answer is nothing, I will start there.

What this part is doingThe close names a specific question the author will ask and where the answer will be recorded. The unresolved disagreement is reported honestly rather than smoothed over, which shows the seminar's reasoning in full.
4

References

Kales, H. C., Gitlin, L. N., & Lyketsos, C. G. (2014). Management of neuropsychiatric symptoms of dementia in clinical settings: Recommendations from a multidisciplinary expert panel. Journal of the American Geriatrics Society, 62(4), 762-769. https://doi.org/10.1111/jgs.12730

Lee, D., Slomkowski, M., Hefting, N., Chen, D., Larsen, K. G., Kohegyi, E., Hobart, M., Cummings, J. L., & Grossberg, G. T. (2023). Brexpiprazole for the treatment of agitation in Alzheimer dementia: A randomized clinical trial. JAMA Neurology, 80(12), 1307-1316. https://doi.org/10.1001/jamaneurol.2023.3810

Otsuka America Pharmaceutical. (2023). Rexulti (brexpiprazole) tablets: Prescribing information. Otsuka America Pharmaceutical.

How this MN663 Unit 6 example is structured

Order follows the writer's position as it moved, not the order of the case. Opening confidence is stated without apology, because the grade depends on showing distance traveled. The pain question is placed at the turning point and quoted as the classmate asked it. From there the reflection sets out the decision the group reached as a sequence rather than a verdict: treat the knee pain and reassess, move the shower to mid-morning when she is most settled, track episodes on a simple log for four weeks, and reconsider medication only if agitation remains severe and dangerous. The DICE approach is named as the structure the group borrowed. One disagreement is recorded honestly, whether four weeks is too long if an aide is hurt meanwhile. Two sources close the page: the prescribing information and Kales and colleagues (2014).

Get an MN663 Unit 6 example written to your instructions

Which prescribing decision did your MN663 seminar argue in Unit 6, and where did you stand before it began? A few lines will do, or the written alternative's prompt, plus the rubric. Once it arrives, free on a first request and within 24-48h, the reflection will show that position, the question that moved it, the evidence checked and one disagreement kept open. The paper above is an original model document written by our desk, not a submitted student paper and not an official Purdue University Global document.

MN663 Unit 6 questions, answered

Can the reflection defend a view the writer still holds?

Yes. Reflection requires examining a position, not abandoning it. If the seminar left your view intact, show what challenge it met and why it survived. A reflection that reports a view tested and kept, with the reasoning visible, satisfies the rubric as well as one reporting a reversal, provided the challenge is described fairly.

What if I used the written alternative instead of attending live?

Most sections accept the alternative, and the reflection works the same way. Describe the case or question it posed, state what you thought before engaging with it, and identify the reading or argument that tested that view. Where the live session had classmates, the alternative has sources, so let one source play the role of the challenging question.

How much pharmacology belongs in a seminar reflection?

Enough to show the evidence behind the change in thinking, stated accurately. Approval dates, trial outcomes and boxed warnings should be correct and cited. The reflection is not a drug review, though, so keep pharmacology to the facts that moved the argument and let the account of how your reasoning changed carry most of the page.